Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Docosapentaenoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.69 |
| ▸ | PPARG known ✓ | P37231 | 2/20 | 0.69 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.69 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.58 |
| ▸ | FABP3 | P05413 | 9/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | F7 | P08709 | 3/20 | 0.69 |
| ▸ | F3 | P13726 | 3/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | PPARD | Q03181 | 2/20 | 0.69 |
| ▸ | PPARA | Q07869 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linolenic Acid SCHEMBL104456 | 1.00 | FABP3 (0.96) | FABP3ALDH1A1F7F3CYP19A1 | |
| SCHEMBL25403260 | 1.00 | FABP3 (0.96) | FABP3ALDH1A1F7F3CYP19A1 | |
| SCHEMBL29908521 | 0.98 | FABP3 (0.93) | FABP3ALDH1A1F7F3CYP19A1 | |
| SCHEMBL25402321 | 0.98 | FABP3 (0.93) | FABP3ALDH1A1F7F3CYP19A1 | |
| Linolenic Acid SCHEMBL4853105 | 0.96 | FABP3 (0.96) | FABP3ALDH1A1F7F3CYP19A1 | |
| Linolenic Acid SCHEMBL4918659 | 0.96 | FABP3 (0.96) | FABP3ALDH1A1F7F3CYP19A1 | |
| Linolenic Acid SCHEMBL4921337 | 0.96 | FABP3 (0.96) | FABP3ALDH1A1F7F3CYP19A1 | |
| Linolenic Acid SCHEMBL6140641 | 0.96 | FABP3 (0.96) | FABP3ALDH1A1F7F3CYP19A1 | |
| Linolenic Acid SCHEMBL2410422 | 0.96 | FABP3 (0.96) | FABP3ALDH1A1F7F3CYP19A1 | |
| Linolenic Acid SCHEMBL4409873 | 0.96 | FABP3 (0.96) | FABP3ALDH1A1F7F3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025093572-A1 | SOLID DISPERSION COMPOSITIONS AND USES THEREOF | TRx Biosciences Limited (GB) | 2025-05-08 | — | — | WO | claimed |
| EP-4493178-A1 | FIBRATE COMPOSITIONS FOR TREATING INFLAMMATION AND NEUROINFLAMMATION | TRX Biosciences Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| EP-4493151-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS AND USES THEREOF | TRX Biosciences Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| EP-4312978-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS | TRX Biosciences Limited (GB) | 2024-02-07 | — | — | EP | claimed |
| WO-2023174948-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS AND USES THEREOF | TRx Biosciences Limited (GB) | 2023-09-21 | — | — | WO | claimed |
| WO-2023174941-A1 | FIBRATE COMPOSITIONS FOR TREATING INFLAMMATION AND NEUROINFLAMMATION | TRx Biosciences Limited (GB) | 2023-09-21 | — | — | WO | claimed |
| WO-2022207580-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS | TRx Biosciences Limited (GB) | 2022-10-06 | — | — | WO | claimed |
| US-20250195433-A1 | Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof | TRx Biosciences Limited (GB) | 2025-06-19 | — | — | US | disclosed |
| WO-2025093572-A1 | SOLID DISPERSION COMPOSITIONS AND USES THEREOF | TRx Biosciences Limited (GB) | 2025-05-08 | — | — | WO | disclosed |
| CN-119677509-A | Fibrate composition for the treatment of inflammation and neuroinflammation | 特瑞克思生物科学有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12226484-B2 | Compositions having improved bioavailability of therapeutics | TRx Biosciences Limited (GB) | 2025-02-18 | — | — | US | disclosed |
| EP-4493151-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS AND USES THEREOF | TRX Biosciences Limited (GB) | 2025-01-22 | — | — | EP | disclosed |
| EP-4493178-A1 | FIBRATE COMPOSITIONS FOR TREATING INFLAMMATION AND NEUROINFLAMMATION | TRX Biosciences Limited (GB) | 2025-01-22 | — | — | EP | disclosed |
| US-20240075147-A1 | Compositions Having Improved Bioavailability of Therapeutics | TRx Biosciences Limited (GB) | 2024-03-07 | — | — | US | disclosed |
| EP-4312978-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS | TRX Biosciences Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023174941-A1 | FIBRATE COMPOSITIONS FOR TREATING INFLAMMATION AND NEUROINFLAMMATION | TRx Biosciences Limited (GB) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023174948-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS AND USES THEREOF | TRx Biosciences Limited (GB) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022207580-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS | TRx Biosciences Limited (GB) | 2022-10-06 | — | — | WO | disclosed |
| US-20220305125-A1 | Compositions Having Improved Bioavailability of Therapeutics | TRx Biosciences Limited (GB) | 2022-09-29 | — | — | US | disclosed |